Device Trial Radar · NCT06483750
Preoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland Dysfunction
Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jun 3, 2024
Primary completion
Feb 1, 2025
Study completion Feb 1, 2025
Sponsor
- Lead sponsor
- George Washington UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 3, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This prospective study will investigate the effect of pre-operative Systane iLux system administration in treated cataract induced dry eye disease.
Conditions
- Dry Eye Disease
- Meibomian Gland Dysfunction
- Cataract Senile
- Dry Eye Syndromes
Interventions
Systane iLux TreatmentDevice
The Systane iLux is an approved thermal pulsation device to treat dry eye disease. The application of heat and compression to both eyelids melts meibum in the obstructed glands to restore the secretion and production of meibum to the eye. The Systane iLux will only be administered to the eye to undergo cataract surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Lipid Layer Thickness (LLT) From 2 Weeks Pre-operative Baseline to 4 Weeks Post-operative Follow-upTime frame: Baseline (2 weeks prior to cataract surgery) and 4 weeks after cataract surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
George Washington University
Washington D.C., District of Columbia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.